

<b>FORM PTO-1449</b> <b>INFORMATION DISCLOSURE STATEMENT</b>	<b>ATTORNEY DOCKET NO.</b> <b>PI4862USW</b>	<b>SERIAL NO.</b> <b>10/521,159</b>
	<b>APPLICANT:</b> Alvaro et al.	
	<b>FILING DATE:</b> <b>August 11, 2005</b>	<b>GROUP</b> <b>1626</b>

### U.S. PATENT DOCUMENTS

Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

Continue on page \_\_\_\_\_

### FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No
WO 93/01169	Jan. 21, 1993	WIPO			
WO 94/04494	Mar. 3, 1994	WIPO			
JP 04/089478	Mar. 23, 1992	JAPAN			

Continue on page \_\_\_\_\_

### OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

	Muller, G.W., et al. "Structural Modifications of Thalidomide Produce Analogs With Enhanced Tumor Necrosis Factor Inhibitory Activity." Journal of Medicinal Chemistry, American Chemical Society, Vol. 39, No. 17, August 16, 1996, pgs. 3238-3240.
	Erion, M.D. "Structure-Based Design of Inhibitors of Purine Nucleoside Phosphorylase. 3. 9-Arylmethyl Derivatives of 9-Deazaguanine Substituted on the Arylmethyl Group." J. Med. Chemistry, Vol. 36, No. 24, 1993, pgs 3771-3783.

Continue on page \_\_\_\_\_

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	